ADOCIA: Shareholder Newsletter
22 December 2014 - 5:30PM
Business Wire
Regulatory News:
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 - ADOC):
shareholder newsletter and invitation to two conference calls.
Dear shareholders,
Today is a great day for Adocia. First of all, I would like to
thank you for your trust and support during these past difficult
years that materialized in the best possible way with the license
agreement on BioChaperone Lispro, one of our lead products, with
Eli Lilly, a major actor in insulin treatment.
This agreement is key for the future development of Adocia since
it will give us a solid financial positioning that will help us
grow in good conditions. It also brings forward the unique value of
our BioChaperone technology on which most of our products which are
currently being developed are based on.
The opportunity which we’ve had to rekindle ties with our former
partner is particularly important since the ceasing of our previous
collaboration created skepticism about the potential of our
BioChaperone technology. Today, all of the conditions were mutual.
On our side, the positive results we got with BioChaperone
underlined the uniqueness of our innovative approach. On Eli
Lilly’s side, they were able to evaluate the strategic importance
of BioChaperone in their portfolio, after having seen the results
of Adocia.
I invite you to join of the two conference calls we set-up:
- On Monday December 22nd at 6pm (CET) in
French. Dial-in number : 01.70.77.09.21.
- On Tuesday December 23rd at 6pm (CET)
in English. Dial-in number: +33 (0)1.70.77.09.42.
During these conference calls, we will brief you on our
agreement with Eli Lilly and will keep you up to date regarding
ongoing projects.
Gerard SoulaCEO and Chairman, Adocia
About ADOCIA
To be a global leader in the innovative delivery of insulins
and therapeutic proteins
ADOCIA is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
already-approved therapeutic proteins. It has a particularly strong
expertise in the field of insulins. ADOCIA’s proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and safety of therapeutic proteins and their ease of
use for patients.
ADOCIA has successfully completed two Phase I and IIa studies of
a fast-acting human insulin formulation (HinsBet®), one Phase I and
two Phase IIa studies of an ultra-fast-acting insulin lispro
(BioChaperone® Lispro U100) and a Phase I/II of a unique
combination of insulin glargine, the gold-standard of basal insulin
and insulin lispro, a fast-acting insulin analog (BioChaperone®
Combo). A Phase IIa study of HinsBet is ongoing and a
dose-escalation Phase IIa study of BioChaperone Combo is scheduled
for the fourth quarter 2014. The company is also preparing a first
clinical study of a new ultra-fast concentrated insulin formulation
based on insulin lispro for 2015. ADOCIA also completed one Phase
I/II clinical study of its product based on PDGF-BB for treating
diabetic foot ulcer (BC PDGF-BB). A Phase III clinical study was
launched in India in August 2014. ADOCIA has extended its
activities to the formulation of monoclonal antibodies, which are
gold-standard biologics for the treatment of various chronic
pathologies (cancer, inflammation, etc.). ADOCIA is engaged in
collaborative programs with two major pharmaceutical companies in
this field.
Fighting cancer with targeted treatments
DriveIn® is a nanotechnology which is remarkably efficient in
delivering active compounds into cancer cells. This new platform
constitutes an exceptional opportunity to enter the oncology market
by improving the efficacy of both already approved treatments and
novel proprietary molecules.
“Innovative medicine for everyone, everywhere”
ADOCIA’s therapeutic innovations aim to provide solutions in a
profoundly changing global pharmaceutical and economic context,
characterized by (i) an increased prevalence and impact of the
targeted pathologies, (ii) a growing and ageing population, (iii) a
need to control public health expenditures and (iv) an increasing
demand from emerging countries.
ADOCIA is listed on the regulated market of Euronext Paris
(ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA,
ADOC.FP) and is included in the Next Biotech index.
American Depositary Receipts representing ADOCIA common stock
are traded on the US OTC market under the ticker symbol ADOCY.
For more information, visit www.adocia.com
Disclaimer
This press release contains certain forward-looking statements
concerning ADOCIA and its business. Such forward-looking statements
are based on assumptions that ADOCIA considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
‘Risk Factors’ section of the Reference Document registered by the
Autorite des marches financiers on April 24, 2014 under number
R.14-020 (a copy of which is available on www.adocia.com) and to
the development of economic conditions, financial markets and the
markets in which ADOCIA operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to ADOCIA or not currently considered material by ADOCIA. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of ADOCIA to be
materially different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
ADOCIA shares in any jurisdiction.
ADOCIAGerard Soula, +33 4 72 610 610Chairman and CEO of
ADOCIAcontactinvestisseurs@adocia.comorPress
RelationsALIZE RPCaroline Carmagnol, +33 170
225 390caroline@alizerp.comadocia@alizerp.com
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024